AbbVie's Skyrizi Poised To Enter Packed Psoriasis Market

AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.

CarPark
AbbVie Hopes To Find Decent Space For Skytrizi • Source: Shutterstock

AbbVie Inc.'s bid to offset the impact of declining revenues in Europe from its off-patent mega blockbuster Humira has been boosted by a recommendation by the continent's regulators for one of the products seen as vital in lifting the US major's future fortunes, the psoriasis therapy Skyrizi.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Skyrizi (risankizumab),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category